Frequently Asked Questions

Yes.

Dogs receiving KBr should be carefully monitored when changing diets, administering chloride-containing IV fluids, and administering concurrent medications. Careful monitoring is important in dogs that have a condition that may cause difficulty maintaining electrolyte balance.

Please consult your veterinarian if seizure frequency increases. The total recommended daily dosage range for oral administration is 25–68 mg/kg (11–31 mg/lb) of body weight. The dosage of KBroVet should be adjusted based on monitoring of clinical response of the individual dog.

Yes, the tablets contain a proprietary flavoring to increase acceptance by dogs.

Tablets are not scored, nor can tablet uniformity across the tablet be guaranteed. It is not recommended that the tablets be split.

Store at controlled room temperature 20–25°C (68–77°F). Keep out of reach of children and animals. Additionally, clients should be advised to keep KBroVet in a secured location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

The two products are labeled differently due the FDA’s approval of KBroVet. Please see the full product label and package insert for details. Additionally, the tablets are no longer scored, nor contain cyanocobalamin (vitamin B-12). All other ingredients remain the same.

The active ingredient, potassium bromide, is thought to exert its antiepileptic activity by passing through neuronal chloride ion channels, thereby hyperpolarizing neuronal membranes. With the neuronal membranes more negatively charged, this decreases the action potential across the synapse, thus raising the seizure threshold and stabilizing neurons against excitatory input from epileptic foci.

The most commonly reported side effects were increased appetite and thirst, increased urination, weight gain, sedation, and ataxia. For full prescribing information see the package insert by clicking here.

KBroVet should not be used in animals with a history of hypersensitivity to bromide. Please see full product label and package insert for all labeled contraindications, warning and precautions.

This is a step forward for the product in the eyes of the FDA. Thanks to a close partnership with the FDA and due to a recognized marketplace need, PRN® Pharmacal has manufactured KBroVet for nearly a decade as an unapproved drug while working toward completion of a formal approval. Recently, the FDA granted conditional approval based on reasonable expectation of efficacy, demonstrated safety, and approval of manufacturing controls.